BridGene Biosciences Raises $28M in Series B+ Round Led by Bayland Capital

Deal Summary

BridGene Biosciences completed a $28M Series B+ financing to advance its small-molecule drug pipeline, including clinical-stage covalent TEAD inhibitor BGC-515. The round was led by Bayland Capital with participation from GTJA Investment Group, Proxima Ventures and existing investors Lapam Capital and Grains Valley Venture Capital.